The five key things you need to know to manage adult patients with sickle cell disease

Hematology (United States)

Volumn 2015, Issue 1, 2015, Pages 420-425

  Lanzkron, Sophie ^a   Haywood, Carlton ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ENOXAPARIN; HEMOGLOBIN; HYDROXYUREA; MORPHINE; OXYCODONE; URATE; URIC ACID; HEMOGLOBIN S;

ACUTE CHEST SYNDROME; ADULT; ALLOIMMUNIZATION; ANALGESIA; ARM PAIN; ARTHRALGIA; ARTICLE; ASYMPTOMATIC DISEASE; BACKACHE; BLOOD VESSEL OCCLUSION; BREAKTHROUGH PAIN; CHRONIC PAIN; CLINICAL ARTICLE; DISORDERS OF HIGHER CEREBRAL FUNCTION; DYSPNEA; EMERGENCY WARD; ERYTHEMA; ERYTHROCYTE TRANSFUSION; FEMALE; GOUT; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEMOGLOBIN SC DISEASE; HEMOLYSIS; HEPARINIZATION; HOSPITAL ADMISSION; HUMAN; JOINT ASPIRATION; JOINT SWELLING; KIDNEY DISEASE; LEG PAIN; LUNG EMBOLISM; MALE; METATARSOPHALANGEAL JOINT; MONTREAL COGNITIVE ASSESSMENT; PAIN ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PROTEINURIA; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; THORAX PAIN; TREATMENT REFUSAL; URIC ACID BLOOD LEVEL; URINALYSIS; VENOUS THROMBOEMBOLISM; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT; ANEMIA, SICKLE CELL; BLOOD; COMPLICATION; HEMATOLOGY; ONCOLOGY; PROCEDURES;

ADULT; ANEMIA, SICKLE CELL; CHRONIC PAIN; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOLOGY; HEMOGLOBIN, SICKLE; HUMANS; KIDNEY DISEASES; MALE; MEDICAL ONCOLOGY; NEUROCOGNITIVE DISORDERS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 85010987763     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2015.1.420     Document Type: Article

References (46)

1. Haywood C Jr, Beach MC, Lanzkron S, et al. A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J Natl Med Assoc. 2009;101(10):1022-1033.
2. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94-101.
3. Dampier C, LeBeau P, Rhee S, et al. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011;86(2): 203-205.
4. Dampier C, Ely B, Brodecki D, O'Neal P. Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. J Pain. 2002;3(6):461-470.
5. Chapman CR, Tuckett RP, Song CW. Pain and stress in a systems perspective: reciprocal neural, endocrine, and immune interactions. J Pain. 2008;9(2):122-145.
6. Michaels LA, Ohene-Frempong K, Zhao H, Douglas SD. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood. 1998;92(9):3148-3151.
7. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2-S15.
8. Ruscheweyh R, Sandkuhler J. Opioids and central sensitisation: II. Induction and reversal of hyperalgesia. Eur J Pain. 2005;9(2):149-152.
9. Moscou-Jackson G, Campbell C, Finan P, et al. Identifying central sensitization in adults with sickle cell disease: differences in clinical features and psychobehavioral factors. J Pain. 2015;16(4):S31.
10. Yawn BP BG, Afenyi-Annan AN, Ballas SK, et al. Evidence Based Management of Sickle Cell Disease. Bethesda, MD: National Heart and Blood Institute; 2014.
11. Neumayr LD, Aguilar C, Earles AN, et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease:results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am. 2006;88(12):2573-2582.
12. Carroll CP, Haywood C Jr, Fagan P, Lanzkron S. The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization. Am J Hematol. 2009;84(10):666-670.
13. Carroll CP, Haywood C Jr, Lanzkron S. Prediction of onset and course of high hospital utilization in sickle cell disease. J Hosp Med. 2011;6(5):248-255.
14. Institute for Clinical Systems Improvement. Assessment and Management of Chronic Pain. Institute for Clinical Systems Improvement, 2013. Accessed July 31, 2015. https://www.icsi.org/guidelines-more/catalog-guidelines-and-more/catalog-guidelines/catalog-neurological guidelines/pain/
15. American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2010;112(4):810-833.
16. Gold JI, Johnson CB, Treadwell MJ, Hans N, Vichinsky E. Detection and assessment of stroke in patients with sickle cell disease: neuropsychological functioning and magnetic resonance imaging. Pediatr Hematol Oncol. 2008;25(5):409-421.
17. Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011;117(4): 1130-1140.
18. Vichinsky EP, Neumayr LD, Gold JI, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA. 2010;303(18):1823-1831.
19. Mackin RS, Insel P, Truran D, et al. Neuroimaging abnormalities in adults with sickle cell anemia: associations with cognition. Neurology. 2014;82(10):835-841.
20. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
21. Rossetti HC, Lacritz LH, Cullum CM, Weiner MF. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology. 2011;77(13):1272-1275.
22. Cichowitz C, Carroll CP, Strouse JJ, Haywood C Jr, S L. Screening for Neurocognitive Dysfunction in an Adult Population with Sickle Cell Disease. Blood. 2014: Abstract 2717.
23. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA. 2014;312(24):2684-2686.
24. Herrera J, Avila E, Marin C, odriguez-Iturbe B. Impaired creatinine secretion after an intravenous creatinine load is an early characteristic of the nephropathy of sickle cell anaemia. Nephrol Dial Transplant. 2002;17(4):602-607.
25. Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med. 1997;102(2):171-177.
26. Gupta S, Yui JC, Xu D, et al. Gout and sickle cell disease: not all pain is sickle cell pain. Br J Haematol. Prepublished on April 20, 2015, as DOI 10.1111/bjh.13433.
27. Lima CS, Bottini PV, Garlipp CR, Santos AO, Costa FF, Saad ST. Accuracy of the urinary albumin to creatinine ratio as a predictor of albuminuria in adults with sickle cell disease. J Clin Pathol. 2002;55(12): 973-975.
28. Foucan L, Bourhis V, Bangou J, Merault L, Etienne-Julan M, Salmi RL. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. Am J Med. 1998;104(4):339-342.
29. Huang E, Parke C, Mehrnia A, et al. Improved survival among sickle cell kidney transplant recipients in the recent era. Nephrol Dial Transplant. 2013;28(4):1039-1046.
30. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program. 2007:91-96.
31. Qari MH, Dier U, Mousa SA. Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clin Appl Thromb Hemost. 2012;18(2):195-200.
32. Hatzipantelis ES, Pana ZD, Gombakis N, et al. Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease. Int J Hematol. 2013;98(2):158-163.
33. Ataga KI, Moore CG, Hillery CA, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica. 2008;93(1):20-26.
34. Naik RP, Streiff MB, Haywood C, Jr., Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013;126(5):443-449.
35. Naik RP, Streiff MB, Haywood C Jr, Segal JB, Lanzkron S. Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. J Thromb Haemost. 2014;12(12):2010-2016.
36. Porter B, Key NS, Jauk VC, Adam S, Biggio J, Tita A. Impact of sickle hemoglobinopathies on pregnancy-related venous thromboembolism. Am J Perinatol. 2014;31(9):805-809.
37. Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol. 2008;199(2):125.e1-5.
38. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311-1315.
39. Seaman CD, Yabes J, Li J, Moore CG, Ragni MV. Venous thromboembolism in pregnant women with sickle cell disease: a retrospective database analysis. Thromb Res. 2014;134(6):1249-1252.
40. Schmidt M, Geilenkeuser WJ, Sireis W, Seifried E, Hourfar K. Emerging pathogens-how safe is blood? Transfus Med Hemother. 2014;41(1):10-17.
41. Kacker S, Ness PM, Savage WJ, et al. Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients. Transfusion. 2014;54(1):86-97.
42. Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion. 2008;48(6):1231-1238.
43. Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009;49(9):1785-1792.
44. Pack-Mabien A, Brown B, Herbert DE, Haynes J Jr. Iron overload in adults with sickle cell disease who have received intermittent red blood cell transfusions. J Am Assoc Nurse Pract. 2015. Prepublished on February 25, 2015, as DOI 10.1002/2327-6924.12221.
45. Jordan L, Adams-Graves P, Kanter-Washko J, et al. Multicenter COMPACT study of complications in patients with sickle cell disease and utilization of iron chelation therapy. Curr Med Res Opin. 2015;31(3): 513-523.
46. Creary SJ. Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease: A Pocket Guide for the Clinician. Washington, DC: American Society of Hematology; 2014.